News
Biotech is increasingly financed, governed and regulated as though it were a mature pharmaceutical industry rather than a discovery system built around scientific uncertainty. Structural changes are needed to sustain the sector’s strategic innovation.
FEATURED STORIES
Nusano will bring a massive new radioisotope facility in Salt Lake City online by the end of the year, establishing a supply of starting materials for the next generation of radiopharmaceuticals.
Last month, Revolution Medicines’ RAS inhibitor doubled survival in a Phase 3 pancreatic cancer trial. On the biotech’s heels are Immuneering, Actuate Therapeutics, Erasca and more, looking to improve on that result with increased tolerability—and more time for patients.
The recent approval of Regeneron’s Otarmeni underscores the maturation of gene therapies across a range of diseases. Here, BioSpace reviews genetic medicines in development for the central nervous system, retinal, cardiac and neuromuscular diseases.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
The Department of Health and Human Services is spinning its wheels, unable to establish steady leadership at three major divisions—the CDC and the FDA’s two primary review units.
THE LATEST
Sanofi will study its SAR444245 in combination with Immunocore’s KIMMTRAK in HLA-A*02:01 positive patients with advanced unresectable or metastatic skin cancers.
In order to stay afloat while maintaining a competitive edge, many life science companies are going to have to get creative in order to keep up with rising salaries and inflation.
Biogen and Ionis Pharmaceuticals have announced results from the Phase III VALOR trial and an open-label extension (OLE) trial of tofersen.
Proxygen partnered with Germany-based Merck to jointly identify and develop molecular glue degraders for clinical research.
Bristol Myers Squibb announced Friday that it is acquiring San Diego-based Turning Point Therapeutics in a deal totaling about $4.1 billion.
June is starting off with a number of important dates for the FDA, including an advisory committee meeting to discuss COVID-19 vaccines in children as young as six months.
BioSpace spoke with Payton Nyquvest, co-founder and CEO of Numinus about changing perceptions around psychedelic-assisted psychotherapy and the company’s work in this space.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Centessa announced Thursday it is discontinuing the development of its lead asset, lixivaptan, for autosomal dominant polycystic kidney disease (ADPKD).
Bristol Myers Squibb’s Orencia and Johnson & Johnson’s Remicade improved survival rates for people hospitalized with COVID-19 according to a new report by the National Institutes of Health.